Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral melatonin for neonatal respiratory distress syndrome
IRCT20130308012743N3Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of melatonin in respiratory distress syndrome (RDS) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Oxidant test, C-reactive protein and 2 more. Started Aug 2022; status: completed.
02
Drugs
melatonin
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on IRCT20130308012743N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130308012743N3.